A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency

Pembrolizumab is an anti-programmed cell death protein-1 antibody that is mainly used for the treatment of non-small cell lung cancer (NSCLC). Immune-related adverse events can be caused by immune checkpoint inhibitors; however, few case reports evaluate the prognosis of patients with NSCLC with lat...

Full description

Bibliographic Details
Main Authors: Kei Sonehara, Kazunari Tateishi, Taro Hirabayashi, Taisuke Araki, Yuichi Ikuyama, Ryosuke Machida, Masayuki Hanaoka
Format: Article
Language:English
Published: Karger Publishers 2021-01-01
Series:Case Reports in Oncology
Subjects:
adrenal insufficiency
immune-related adverse events
lung adenocarcinoma
pembrolizumab
prognostic factor
Online Access:https://www.karger.com/Article/FullText/508068

Similar Items

Similar Items